Advertisement
ABVX vs XENE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABVX is a Buy and XENE is a Buy.
ABVX's RSI Indicator ascending out of oversold territory
The RSI Oscillator for ABVX moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 18 similar instances when the indicator left oversold territory. In 16 of the 18 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 23 of 31 cases where ABVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ABVX as a result. In 35 of 50 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for ABVX just turned positive on October 14, 2026. Looking at past instances where ABVX's MACD turned positive, the stock continued to rise in 31 of 38 cases over the following month. The odds of a continued upward trend are 82%.
Following a +6.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABVX advanced for three days, in 154 of 182 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 50-day moving average for ABVX moved below the 200-day moving average on September 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ABVX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ABVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.499) is normal, around the industry mean (2.973). P/E Ratio (-16.929) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (192.308) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
XENE's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for XENE turned positive on October 07, 2026. Looking at past instances where XENE's MACD turned positive, the stock continued to rise in 44 of 49 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XENE's RSI Oscillator exited the oversold zone, 21 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on XENE as a result. In 64 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
Following a +8.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in 195 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
XENE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for XENE moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for XENE entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.845) is normal, around the industry mean (2.973). P/E Ratio (-7.700) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (1.930) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (588.235) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. XENE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
XENE | ||
|---|---|---|
OUTLOOK RATING 1..100 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 64 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 80 | |
P/E GROWTH RATING 1..100 | 11 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ABVX | XENE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 89% | 1 day ago 78% |
| Stochastic ODDS (%) | 1 day ago 74% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 72% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 71% |
| Advances ODDS (%) | 2 days ago 85% | 3 days ago 67% |
| Declines ODDS (%) | 4 days ago 81% | 9 days ago 68% |
| BollingerBands ODDS (%) | N/A | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABVX’s FA Score shows that 1 FA rating(s) are green while XENE’s FA Score has 1 green FA rating(s).
- ABVX’s FA Score: 1 green, 4 red.
- XENE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABVX’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).
- ABVX’s TA Score: 5 bullish, 3 bearish.
- XENE’s TA Score: 5 bullish, 3 bearish.
Price Growth
ABVX (@Biotechnology) experienced а -2.33% price change this week, while XENE (@Biotechnology) price change was +6.32% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
ABVX is expected to report earnings on Dec 14, 2026.
XENE is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
XENE and
Correlation & Price change
A.I.dvisor indicates that over the last year, XENE has been loosely correlated with RLMD. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then RLMD could also see price increases.
| Ticker / NAME | Correlation To XENE | 1D Price Change % | ||
|---|---|---|---|---|
| XENE | 100% | +1.53% | ||
| RLMD - XENE | 50% Loosely correlated | +2.49% | ||
| DNTH - XENE | 45% Loosely correlated | +0.55% | ||
| MLTX - XENE | 44% Loosely correlated | +15.87% | ||
| REPL - XENE | 42% Loosely correlated | +2.30% | ||
| DYN - XENE | 39% Loosely correlated | -1.87% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NMZ | 9.05 | 0.07 | +0.78% |
| Nuveen Municipal High Income Opportunity Fund | |||
| IGHG | 77.42 | -0.08 | -0.10% |
| ProShares Investment Grade-Interest Rate Hedged (IGHG) | |||
| IBHL | 24.31 | -0.09 | -0.37% |
| iShares iBonds 2032 Term High Yield and Income ETF (IBHL) | |||
| JADB | 26.34 | -0.18 | -0.70% |
| Aptus January Deep Buffer ETF (JADB) | |||
| DWUS | 58.10 | -1.09 | -1.83% |
| AdvisorShares Dorsey Wright FSM US Core ETF (DWUS) | |||